5023-94-9

Basic information

• Product Name: 3-NITROBENZAMIDOXIME
• Synonyms: 3-NITRO-BENZAMIDOXIME;N-HYDROXY-3-NITRO-BENZAMIDINE;N'-HYDROXY-3-NITROBENZENECARBOXIMIDAMIDE;N-HYDROXY-3-NITRO-BENZENECARBOXIMIDAMIDE;m-nitrobenzamide oxime;N-Hydroxy-3-nitrobenzimidamide;Benzenecarboximidamide, N-hydroxy-3-nitro-
• CAS NO: 5023-94-9
• Molecular Formula: C₇H₇N₃O₃
• Molecular Weight: 181.15
• EINECS: 225-709-4
• Product Categories: pharmacetical
• Mol File: 5023-94-9.mol
• Article Data: 18

Chemical Properties

• Melting Point: 180-182 °C(Solv: toluene (108-88-3))
• Boiling Point: 400.6 °C at 760 mmHg
• Flash Point: 196.1 °C
• Appearance: /
• Density: 1.49 g/cm³
• Vapor Pressure: 3.87E-07mmHg at 25°C
• Refractive Index: 1.643
• PKA: 13.27±0.50(Predicted)
• CAS DataBase Reference: 3-NITROBENZAMIDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 3-NITROBENZAMIDOXIME(5023-94-9)
• EPA Substance Registry System: 3-NITROBENZAMIDOXIME(5023-94-9)

Safety Data

• Hazardous Substances Data: 5023-94-9(Hazardous Substances Data)

Usage

Description

3-NITROBENZAMIDOXIME, with the molecular formula C7H6N4O3, is a yellowish solid chemical compound. It is characterized by the presence of a nitro group and an amidoxime functional group, which contribute to its versatility in chemical reactions. Primarily utilized as a reagent in organic synthesis, this compound is also recognized for its ability to chelate with metal ions, a property that extends its utility across research and industrial applications. Additionally, it serves as a starting material for the synthesis of other organic compounds and pharmaceuticals, and it holds potential in the realms of coordination chemistry and the development of metal-based drugs.

Uses

Used in Organic Synthesis:
3-NITROBENZAMIDOXIME is used as a reagent in organic synthesis for its capacity to participate in various chemical reactions, facilitating the creation of a range of organic compounds.
Used in Research and Industrial Applications:
In research and industrial settings, 3-NITROBENZAMIDOXIME is employed for its metal-chelating properties, which are valuable in numerous applications, including the development of new materials and processes.
Used as a Starting Material for Pharmaceutical Synthesis:
3-NITROBENZAMIDOXIME is utilized as a starting material in the synthesis of pharmaceuticals, owing to its ability to be transformed into other compounds with potential medicinal properties.
Used in Coordination Chemistry:
3-NITROBENZAMIDOXIME is applied in the field of coordination chemistry, where its interaction with metal ions is exploited to study and develop new coordination complexes.
Used in the Development of Metal-Based Drugs:
3-NITROBENZAMIDOXIME holds promise in the development of metal-based drugs, capitalizing on its chelating capabilities to enhance the therapeutic potential of metal ions in medicinal applications.

InChI:InChI=1/C7H7N3O3/c8-7(9-11)5-2-1-3-6(4-5)10(12)13/h1-4,11H,(H2,8,9)

Upstream product

• 64-17-5 ethanol 
• 7803-49-8 hydroxylamine 
• 619-24-9 3-nitrobenzonitrile 
• 3459-99-2 3-nitrobenzamidine 
• 67-56-1 methanol 
• 172469-58-8 4-(3-Nitro-phenyl)-2λ⁴-[1,2,3,5]oxathiadiazol-2-ylamine 
• 7007-35-4 m-nitrobenzonitrile oxide 
• 503027-47-2 N,N'-bis(trimethylsilyl)sulfurdiimide 
• 33512-94-6 m-nitrobenzhydroxamoyl chloride 
• 585-79-5 m-nitrobromobenzene 
• 100-47-0 benzonitrile 
• 3431-62-7 3-nitrobenzaldoxime 

Downstream Products

• 1041005-78-0 N-cyclohexyl-3-(3-nitrophenyl)-1,2,4-oxadiazol-5-amine 
• 25283-98-1 5-methyl-3-(3-nitro-phenyl)-[1,2,4]oxadiazole 
• 20844-48-8 3-(3-nitrophenyl)-5-phenyl-1,2,4-oxadiazole 
• 100524-07-0 3-amino-N'-hydroxybenzenecarboximidamide 
• 1041005-69-9 N-isopropyl-3-(3-nitrophenyl)-1,2,4-oxadiazol-5-amine 
• 1028344-66-2 C₁₂H₁₁N₃O₅ 
• 24794-10-3 1-[3-(3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-propan-2-one 
• 81467-53-0 C₁₁H₁₁N₃O₅ 
• 916809-76-2 4-[{[3-(3-Nitrophenyl)-1,2,4-oxadiazol-5-yl]methyl}(2,2,2-trifluoroethyl)amino]-2-(trifluoromethyl)benzonitrile 
• 134285-42-0 C₉H₉N₃O₄ 

Relevant articles and documents

Synthesis, in silico, and in vitro evaluation of anti-leishmanial activity of oxadiazoles and indolizine containing compounds flagged against anti-targets

Due to the lack of approved vaccines against human leishmaniasis and the limitations of the current chemotherapy inducing side effects and drug resistance, development of new, effective chemotherapeutic agents is essential. This study describes the synthesis of a series of novel oxadiazoles and indolizine-containing compounds. The compounds were screened in silico using an EIIP/AQVN filter followed by ligand-based virtual screening and molecular docking to parasite arginase. Top hits were further screened versus human arginase and finally against an anti-target battery to tag their possible interactions with proteins essential for the metabolism and clearance of many substances. Eight candidate compounds were selected for further experimental testing. The results show measurable in vitro anti-leishmanial activity for three compounds. One compound with an IC50 value of 2.18 μM on Leishmania donovani intramacrophage amastigotes is clearly better positioned than the others as an interesting molecular template for further development of new anti-leishmanial agents.

Synthesis and Evaluation of Antibacterial Activity of 1,2,4-Oxadiazole-Containing Biphenylcarboxylic Acids

Abstract: A one-pot method for the synthesis of biphenylcarboxylic acids containing 1,2,4-oxadiazole ring in the NaOH–DMSO system was developed. The results of in vitro experiments showed that the synthesized compounds exhibit antibacterial activity against susceptible strains of E. coli and S. aureus.

Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents

Abstract In our study, three series of hydroxamate, 2-aminobenzamide, and trifluoromethyl ketone analogues have been designed and synthesized. The synthesized compounds were investigated for their in vitro antiproliferative activities using the MTT-based assay against three human cancer cell lines including A549, NCI-H661, and U937. Most analogues exhibited higher antiproliferative activities against human acute myeloid leukemia cell U937 than the other two human lung cancer cell lines. Furthermore, the compounds were examined against HDAC1, 2, and 8 isoforms. Docking study of compounds 6h, 9b, and 10a suggested that they might bind tightly to the binding pocket of HDAC2 and/or HDAC8. The results suggest that these compounds might have potential as lead compounds for the development of anti-tumor drugs with HDACs inhibitory activities.